Preclinical Models for Neuroblastoma: Establishing a Baseline for Treatment
Author Information
Author(s): Teitz Tal, Stanke Jennifer J., Federico Sara, Bradley Cori L., Brennan Rachel, Zhang Jiakun, Johnson Melissa D., Sedlacik Jan, Inoue Madoka, Zhang Ziwei M., Frase Sharon, Rehg Jerold E., Hillenbrand Claudia M., Finkelstein David, Calabrese Christopher, Dyer Michael A., Lahti Jill M.
Primary Institution: St. Jude Children's Research Hospital
Hypothesis
The study aims to characterize and optimize preclinical models for neuroblastoma to improve the testing of new chemotherapeutic combinations.
Conclusion
The study suggests that both the TH-MYCN model and the orthotopic xenograft model are optimal for testing new chemotherapies for neuroblastoma.
Supporting Evidence
- The TH-MYCN model closely resembles aggressive human neuroblastoma tumors.
- Ultrasound-guided injections provide a minimally invasive method for creating xenografts.
- Chemotherapy regimens based on current treatments showed a baseline for comparison of new agents.
- 10% of TH-MYCN tumors exhibited spontaneous regression, similar to some human cases.
Takeaway
Researchers are trying to find better ways to test new cancer treatments for kids with neuroblastoma by using special mouse models.
Methodology
The study used TH-MYCN transgenic mice and developed a new ultrasound-guided method for orthotopic xenografts to test chemotherapy regimens.
Limitations
The TH-MYCN model has limitations such as low frequency of bone marrow metastasis and variability in tumor penetrance.
Participant Demographics
The study involved hemizygous TH-MYCN transgenic mice, with tumors arising in both male and female mice aged 8-13 weeks.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website